{"id":"https://openalex.org/W4391616337","doi":"https://doi.org/10.1016/j.jtct.2023.12.496","title":"Comparative Study Evaluating Hospitalizations and Critical Care Stays Among Patients with R/R Large B-Cell Lymphoma (LBCL) Treated with CAR T Cell Therapies Lisocabtagene Maraleucel (liso-cel) and Axicabtagene Ciloleucel (axi-cel) in the Inpatient (IP) and Outpatient (OP) Setting Using United States (US) Claims Data","display_name":"Comparative Study Evaluating Hospitalizations and Critical Care Stays Among Patients with R/R Large B-Cell Lymphoma (LBCL) Treated with CAR T Cell Therapies Lisocabtagene Maraleucel (liso-cel) and Axicabtagene Ciloleucel (axi-cel) in the Inpatient (IP) and Outpatient (OP) Setting Using United States (US) Claims Data","publication_year":2024,"publication_date":"2024-02-01","ids":{"openalex":"https://openalex.org/W4391616337","doi":"https://doi.org/10.1016/j.jtct.2023.12.496"},"language":"en","primary_location":{"id":"doi:10.1016/j.jtct.2023.12.496","doi":"https://doi.org/10.1016/j.jtct.2023.12.496","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jtct.2023.12.496","pdf_url":null,"source":{"id":"https://openalex.org/S59987174","display_name":"Transplantation and Cellular Therapy","issn_l":"1083-8791","issn":["1083-8791","1523-6536","2666-6367"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Transplantation and Cellular Therapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.jtct.2023.12.496","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039527687","display_name":"Simran K. Tiwana","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Simran K. Tiwana","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012994671","display_name":"Tracy Krimmel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tracy Krimmel","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026542617","display_name":"Lynn Y Huynh","orcid":"https://orcid.org/0000-0003-3110-6775","observed_orcids":["https://orcid.org/0000-0003-3110-6775"]},"institutions":[{"id":"https://openalex.org/I79463011","display_name":"Analysis Group (United States)","ror":"https://ror.org/044jp1563","country_code":"US","type":"company","lineage":["https://openalex.org/I79463011"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lynn Huynh","raw_affiliation_strings":["Analysis Group, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Boston, MA","institution_ids":["https://openalex.org/I79463011"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101557475","display_name":"Ellen Kim","orcid":"https://orcid.org/0000-0001-9379-0192","observed_orcids":["https://orcid.org/0000-0001-9379-0192"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ellen Kim","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057752136","display_name":"Enrico Zanardo","orcid":"https://orcid.org/0009-0009-7011-1180","observed_orcids":["https://orcid.org/0009-0009-7011-1180"]},"institutions":[{"id":"https://openalex.org/I79463011","display_name":"Analysis Group (United States)","ror":"https://ror.org/044jp1563","country_code":"US","type":"company","lineage":["https://openalex.org/I79463011"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Enrico Zanardo","raw_affiliation_strings":["Analysis Group, Denver, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Denver, CO","institution_ids":["https://openalex.org/I79463011"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113114550","display_name":"J. Klimek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79463011","display_name":"Analysis Group (United States)","ror":"https://ror.org/044jp1563","country_code":"US","type":"company","lineage":["https://openalex.org/I79463011"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacob Klimek","raw_affiliation_strings":["Analysis Group, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Boston, MA","institution_ids":["https://openalex.org/I79463011"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070882299","display_name":"Talissa Watson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Talissa Watson","raw_affiliation_strings":["Analysis Group, Montreal, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Montreal, QC, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093883106","display_name":"Kelvin Tamakloe","orcid":"https://orcid.org/0009-0004-4041-9145","observed_orcids":["https://orcid.org/0009-0004-4041-9145"]},"institutions":[{"id":"https://openalex.org/I79463011","display_name":"Analysis Group (United States)","ror":"https://ror.org/044jp1563","country_code":"US","type":"company","lineage":["https://openalex.org/I79463011"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kelvin Tamakloe","raw_affiliation_strings":["Analysis Group, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Boston, MA","institution_ids":["https://openalex.org/I79463011"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093883107","display_name":"Mihran Yenikomshain","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79463011","display_name":"Analysis Group (United States)","ror":"https://ror.org/044jp1563","country_code":"US","type":"company","lineage":["https://openalex.org/I79463011"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mihran Yenikomshain","raw_affiliation_strings":["Analysis Group, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Boston, MA","institution_ids":["https://openalex.org/I79463011"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016684714","display_name":"David G. Maloney","orcid":"https://orcid.org/0000-0002-8477-6919","observed_orcids":["https://orcid.org/0000-0002-8477-6919"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David G. Maloney","raw_affiliation_strings":["Fred Hutch Cancer Center, Seattle, WA","University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutch Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5039527687"],"corresponding_institution_ids":["https://openalex.org/I4210091812"],"apc_list":{"value":3650,"currency":"USD","value_usd":3650},"apc_paid":{"value":3650,"currency":"USD","value_usd":3650},"fwci":0.1718,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.45685029,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"30","issue":"2","first_page":"S355","last_page":"S355"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-large-b-cell-lymphoma","display_name":"relapsed/refractory large B-cell lymphoma","score":0.843999981880188},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.9440000057220459},{"id":"https://openalex.org/keywords/lisocabtagene-maraleucel","display_name":"lisocabtagene maraleucel","score":0.9559999704360962},{"id":"https://openalex.org/keywords/axicabtagene-ciloleucel","display_name":"axicabtagene ciloleucel","score":1.0},{"id":"https://openalex.org/keywords/inpatient-procedures","display_name":"inpatient procedures","score":0.6520000100135803},{"id":"https://openalex.org/keywords/intensive-care-unit-admission","display_name":"intensive care unit admission","score":0.7360000014305115},{"id":"https://openalex.org/keywords/outpatient-infusion","display_name":"outpatient infusion","score":0.6809999942779541},{"id":"https://openalex.org/keywords/economic-burden","display_name":"economic burden","score":0.5249999761581421},{"id":"https://openalex.org/keywords/real-world-outcomes","display_name":"real-world outcomes","score":0.5989999771118164},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.6449999809265137},{"id":"https://openalex.org/keywords/hospitalization-costs","display_name":"hospital costs","score":0.48899999260902405},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.3179999887943268}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6281092166900635},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.46781086921691895},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4599863588809967},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3107450604438782}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jtct.2023.12.496","doi":"https://doi.org/10.1016/j.jtct.2023.12.496","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jtct.2023.12.496","pdf_url":null,"source":{"id":"https://openalex.org/S59987174","display_name":"Transplantation and Cellular Therapy","issn_l":"1083-8791","issn":["1083-8791","1523-6536","2666-6367"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Transplantation and Cellular Therapy","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.jtct.2023.12.496","doi":"https://doi.org/10.1016/j.jtct.2023.12.496","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jtct.2023.12.496","pdf_url":null,"source":{"id":"https://openalex.org/S59987174","display_name":"Transplantation and Cellular Therapy","issn_l":"1083-8791","issn":["1083-8791","1523-6536","2666-6367"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Transplantation and Cellular Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4417013137","https://openalex.org/W7127349587","https://openalex.org/W4412443863","https://openalex.org/W7127444676","https://openalex.org/W4408415339","https://openalex.org/W3213274776","https://openalex.org/W4391602474","https://openalex.org/W4404402857","https://openalex.org/W4389235327","https://openalex.org/W4410820698"],"abstract_inverted_index":{"Due":[0],"to":[1,16,41,126,389],"the":[2,22,33,60,101,110,116,120,137,155,223,272,283,312,317,393,429],"growing":[3],"use":[4],"of":[5,24,49,104,131,166,178,236,259,286,319,342,403,425],"CAR":[6,105],"T":[7,106],"cell":[8,107],"therapies":[9],"in":[10,32,59,271,392,428],"R/R":[11,28,52,70,372],"LBCL,":[12,29],"it":[13],"is":[14],"crucial":[15],"understand":[17],"their":[18],"economic":[19],"burden":[20,402],"for":[21,149,175,208,277,301,311,415],"treatment":[23],"adult":[25,67],"patients":[26,50,68,197,221,237,260,302,370,418],"with":[27,51,55,69,83,199,203,239,262,267,304,307,335,338,351,354,371,377,387,411,420,439],"including":[30],"DLBCL":[31],"real-world":[34],"setting.":[35,64,274,395],"This":[36],"retrospective":[37],"study":[38,367],"was":[39,98,113,289,329,348],"conducted":[40],"evaluate":[42],"IP":[43,61,161,182,287,320,404,426],"procedures":[44,162,183,288,321,405,427],"and":[45,62,88,109,135,140,168,186,201,215,229,241,245,249,254,264,280,324,406,434],"critical":[46,171,343,407,435],"care":[47,344,408,436],"admissions":[48,169,409],"LBCL":[53,71,86,373],"infused":[54,391],"liso-cel":[56,91,200,228,240,263,305,336,352,378,421],"or":[57,92],"axi-cel":[58,93,202,242,268,355,388],"OP":[63,273,394],"We":[65],"evaluated":[66],"using":[72,360],"a":[73,84,146,150,361,398],"large":[74,362],"US":[75,363],"claims":[76,364],"database,":[77,365],"Symphony":[78],"Health's":[79],"Integrated":[80],"Dataverse":[81],"(01/01/2017\u201305/04/2023),":[82],"confirmed":[85,147],"diagnosis":[87,148],"\u2265":[89,128],"1":[90],"claim.":[94],"The":[95,233,340],"index":[96,121,138,156],"date":[97,139],"defined":[99,114],"as":[100,115],"first":[102],"claim":[103],"infusion":[108,167,190,216,270,281,296,328,347,433],"baseline":[111,416],"period":[112,314],"3":[117,129],"months":[118,130],"before":[119,134,154],"date.":[122,157],"Patients":[123],"were":[124,141,191,194,243,252,375,379],"required":[125],"have":[127],"clinical":[132],"activity":[133],"after":[136,180,189,295,315,327,346,432],"excluded":[142],"if":[143],"they":[144],"had":[145,397,422],"metastatic":[151],"solid":[152],"tumor":[153],"Study":[158],"outcomes":[159],"included":[160],"within":[163,292],"30":[164,187,293,325,430],"days":[165,177,188,294,326,431],"into":[170],"care.":[172],"To":[173],"allow":[174],"7":[176],"monitoring":[179,313],"infusion,":[181,316],"between":[184,196,322],"8":[185,323],"analyzed.":[192],"Outcomes":[193],"compared":[195,306,337,353,410,438],"treated":[198,238,261,266,303,376,386,419],"multivariate":[204],"regression":[205],"models":[206],"adjusting":[207,276,414],"age,":[209,278],"Quan":[210],"Charlson":[211],"Comorbidity":[212],"Index":[213],"(Quan-CCI),":[214],"setting":[217],"(IP/OP).":[218],"Of":[219],"553":[220],"meeting":[222],"eligibility":[224],"criteria,":[225],"103":[226],"received":[227,231,269],"450":[230],"axi-cel.":[232,308,339,412,440],"mean":[234],"age":[235],"69":[244],"61":[246],"years,":[247],"respectively,":[248],"Quan-CCI":[250],"scores":[251],"3.6":[253],"3.3,":[255],"respectively.":[256],"Forty-four":[257],"percent":[258],"10%":[265],"After":[275,413],"Quan-CCI,":[279],"setting,":[282],"adjusted":[284],"risk":[285,318,341,424],"64%":[290],"lower":[291,331,350,401],"(P":[297,332,356],"<":[298],"0.001;":[299],"Figure)":[300],"Furthermore,":[309],"accounting":[310],"73%":[330],"=":[333,357],"0.001)":[334],"admission":[345,437],"56%":[349],"0.037).":[358],"In":[359],"this":[366],"found":[368],"that":[369],"who":[374],"4":[380],"times":[381],"more":[382],"likely":[383],"than":[384],"those":[385],"be":[390],"Liso-cel":[396],"statistically":[399],"significant":[400],"variables,":[417],"reduced":[423]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2024-02-08T00:00:00"}